206201-64-1

Basic information

• Product Name: 3-Pyridinecarbonitrile,6-formyl-(9CI)
• Synonyms: 3-Pyridinecarbonitrile,6-formyl-(9CI);6-Formyl-3-pyridinecarbonitrile
• CAS NO: 206201-64-1
• Molecular Formula: C₇H₄N₂O
• Molecular Weight: 132.12
• Product Categories: PYRIDINE
• Mol File: 206201-64-1.mol

Chemical Properties

• Boiling Point: 280.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.27±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridinecarbonitrile,6-formyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonitrile,6-formyl-(9CI)(206201-64-1)
• EPA Substance Registry System: 3-Pyridinecarbonitrile,6-formyl-(9CI)(206201-64-1)

Safety Data

• Hazardous Substances Data: 206201-64-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research and Development:
3-Pyridinecarbonitrile,6-formyl-(9CI) is used as a reactive compound for the synthesis of new chemical entities. Its nitrile and formyl groups make it a versatile building block in the creation of various organic compounds, particularly in the fields of pharmaceuticals and materials science.
Used in Pharmaceutical Industry:
3-Pyridinecarbonitrile,6-formyl-(9CI) is used as an intermediate in the synthesis of pharmaceutical compounds. Its reactivity allows for the development of new drug candidates with potential therapeutic applications, contributing to the advancement of medicine.
Used in Materials Science:
3-Pyridinecarbonitrile,6-formyl-(9CI) is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of novel products with applications in various industries, such as electronics or coatings.

Upstream product

• 31795-61-6 6-(hydroxymethyl)pyridine-3-carbonitrile 
• 3222-48-8 6-methylnicotinonitrile 
• 16173-99-2 6-ethenylpyridine-3-carbonitrile 
• 1531599-37-7 (E)-6-[2-(dimethylamino)vinyl]nicotinonitrile 

Downstream Products

• 1097207-04-9 C₂₅H₂₄Cl₂N₄O₂ 
• 1427712-21-7 C₂₃H₂₀Cl₂N₄O 
• 170727-00-1 6-formylnicotinonitrile oxime 
• 1625672-29-8 1-((5-cyanopyridin-2-yl)(2-hydroxy-6-oxocyclohex-1-enyl)methyl)-3-(3-(trifluoromethyl)phenyl)urea 

Relevant articles and documents

ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn's disease or ulcerative colitis.

Mechanism of the CuII-catalyzed benzylic oxygenation of (aryl)(heteroaryl)methanes with oxygen

A mechanistic study of the copper-catalyzed oxidation of the methylene group of aryl(di)azinylmethanes was performed. Initial reaction rates were measured making use of in situ IR reaction monitoring and a kinetic analysis of the reaction was executed. The reaction proved to be first order in oxygen concentration. For substrate and acid concentration, saturation kinetics due to O2 mass transfer limitation were observed. The occurrence of mass transfer limitation was further confirmed by examining the effect of the stirring rate on the initial reaction rate. Interestingly, the effect of the concentration of the catalyst on the rate shows that higher loadings result in a maximal initial rate, followed initially by a steady decrease and subsequently a rate plateau when the concentration is increased further. Mass transfer limitation and increased concentration of dinuclear catalytically active species rationalizes this hitherto unprecedented rate behavior. Continuous-wave and pulsed electron paramagnetic resonance methods were used to characterize the catalytic species present in the solution during the reaction and confirmed the presence of both mono- and dinuclear copper species. Analysis of a diverse substrate scope points towards imine-enamine tautomerization as a crucial process in the oxidation reaction. DFT calculations of these equilibrium constants (pKeq) provided us with a qualitative tool to predict whether or not a substrate is viable for oxidation under the reaction conditions developed.

Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues

Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. S

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

BENZISOXAZOLE COMPOUND

Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: -(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: -(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES

The present invention relates to a class of melanocortin MCR4 agonists of general formula (I), wherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS

The invention relates to novel dihydropyridine derivatives, of Formula (I) processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Substituted phenyl farnesyltransferase inhibitors

Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.